Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148968 | 0.85 | HTR5A (0.39) | HTR5AAHRCYP1A2MAPTCYP2C19 | |
| SCHEMBL8203538 | 0.68 | NPFFR2 (0.31) | MAPTKMT2A | |
| SCHEMBL207620 | 0.67 | HTR5A (0.40) | HTR5ACA1CA2AHRCYP1A2 | |
| SCHEMBL7261039 | 0.66 | HTR5A (0.36) | HTR5ACA1CA2 | |
| SCHEMBL7790639 | 0.65 | HTR5A (0.34) | HTR5ACA1CA2PDE3A | |
| SCHEMBL3651634 | 0.65 | HTR5A (0.39) | HTR5ACA1CA2CA12CA4 | |
| SCHEMBL17079530 | 0.64 | HTR5A (0.53) | HTR5ACA1CA2CA12CA4 | |
| SCHEMBL6363808 | 0.64 | CYP3A4 (0.43) | MAPT | |
| SCHEMBL16617635 | 0.64 | KCNH2 (0.32) | HTR5ACA1CA2CA4PDE3A | |
| SCHEMBL207621 | 0.61 | HTR5A (0.39) | HTR5ACA1CA2AHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | HTR5A 1042/4885CA1 4852/4885CA2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.